公开(公告)号：US20230101139A1

公开(公告)日：2023-03-30

申请号：US17788378

申请日：2020-12-25

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Akinori Nishimoto ,  Akiko Kita ,  Saeko Hayashi

IPC: A61K31/519 ,  A61K9/08

Abstract: The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof and having a pH of 4.0 to 6.5.

公开(公告)号：US20230057222A1

公开(公告)日：2023-02-23

申请号：US17793184

申请日：2020-10-19

Applicant: ROHTO PHARMACEUTICAL CO., LTD. ,  RIKEN

Inventor： Shun KIMURA ,  Takashi TSUJI

IPC: G01N33/50

Abstract: An object of the present invention is to provide a new method for evaluating and/or screening an excellent healthcare material or pharmaceutical product based on a new concept. The present invention to solve the above object is a method for evaluating and/or screening a control agent for tissue morphology and/or tissue function, the method including: applying a test substance to a tissue or cell capable of expressing a mechanical stress signaling molecule; and evaluating expression, activity, or intracellular localization of the mechanical stress signaling molecule in the tissue or cell.

公开(公告)号：US11166938B2

公开(公告)日：2021-11-09

申请号：US16313876

申请日：2017-06-28

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Masatoshi Haga ,  Yuya Hayashi

IPC: A61K31/375 ,  A61K8/86 ,  A61P17/10 ,  A61P17/18 ,  A61K31/357 ,  A61P17/00 ,  A61K47/22 ,  A61K8/34 ,  A61K8/41 ,  A61K8/55 ,  A61K8/67 ,  A61K9/00 ,  A61K47/18 ,  A61K47/24 ,  A61Q19/02 ,  A61Q19/08 ,  A61K47/10

Abstract: Provided is an external composition excellent in stability and impression from use. An external composition containing (A) at least one member selected from the group consisting of ascorbic acid and salts of ascorbic acid, (B) at least one member selected from the group consisting of 3-O-ethylascorbic acid, salts of 3-O-ethylascorbic acid, and hydroxylated lecithin, and (C) polyethylene glycol is prepared.

公开(公告)号：US20210052481A1

公开(公告)日：2021-02-25

申请号：US16958389

申请日：2018-12-27

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yu KITAOKA ,  Masatoshi HAGA

IPC: A61K8/67 ,  A61K8/34 ,  A61K8/41 ,  A61Q19/08 ,  A61Q19/02

Abstract: The present invention provides an external composition superior in stability and use feeling. According to the present invention, an external composition is prepared which includes (A) at least one selected from the group consisting of an ascorbic acid and an ascorbic salt, (B) a diol having 3 carbon atoms, (C) at least one selected from the group consisting of a low-molecular-weight betaine, an organic acid salt, an inorganic acid salt, a basic amino acid, a basic amino acid salt, 3-O-ethylascorbic acid, and a 3-O-ethylascorbic acid salt, and (D) water, and a content of ethoxydiglycol of said composition is less than 30 mass %.

公开(公告)号：US20210038616A1

公开(公告)日：2021-02-11

申请号：US16979757

申请日：2019-03-29

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Noriko OHTA ,  Junko MARUKAWA

IPC: A61K31/573 ,  A61K47/06 ,  A61K9/00 ,  A61K31/135

Abstract: A solid oily external composition including at least one selected from the group consisting of (A) a steroid compound and an antihistamine is smoothly applicable onto a skin or a mucous membrane. The composition can be a stick-shaped solid composition. The content of the steroid compound (A) can be 0.0001 to 5% by weight relative to the total amount of the composition, and the content of the antihistamine (B) can be 0.01 to 5% by weight relative to the total amount of the composition.

公开(公告)号：US20200069740A1

公开(公告)日：2020-03-05

申请号：US16491974

申请日：2018-03-08

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Hikari Hasegawa ,  Masayo Yumoto ,  Yoshifumi Ikeyama ,  Hiroyuki Nishida ,  Tomohiro Tsuda ,  Eiko Uno ,  Kazuma Suda ,  Mihoko Yoshino ,  Xuan Trung Ngo

IPC: A61K35/28

Abstract: The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition containing such mesenchymal stem cells. The present invention is a therapeutic agent for fibrosis that contains ROR1-positive mesenchymal stem cells and/or a culture supernatant thereof and that is for preventing or treating a disease associated with fibrosis. The mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive and are preferably derived from the umbilical cord or fat. In addition, the abovementioned disease associated with fibrosis is preferably a liver disease, a lung disease, a kidney disease, or a heart disease.

公开(公告)号：US20200009195A1

公开(公告)日：2020-01-09

申请号：US16490777

申请日：2018-02-22

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yui Ueno ,  Hidenori Nonaka

IPC: A61K35/28 ,  A61P1/16

Abstract: The purpose of the present invention is to provide a novel therapeutic agent for liver disease. The present invention is a mesenchymal stem cell characterized by high expression of the Tissue Factor Pathway Inhibitor (TFPI). It is preferable that the mesenchymal stem cell is allogeneic and is derived from a fatty tissue. Moreover, the present invention includes a therapeutic agent for liver disease containing the mesenchymal stem cell.

公开(公告)号：US20190117701A1

公开(公告)日：2019-04-25

申请号：US16096973

申请日：2017-04-27

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi Ikeyama ,  Eiko Uno ,  Masayo Yumoto ,  Mihoko Yoshino ,  Xuan Trung Ngo ,  Hiroyuki Nishida ,  Akiko Uetani

IPC: A61K35/28 ,  A61P29/00

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.

公开(公告)号：USD845776S1

公开(公告)日：2019-04-16

申请号：US29634107

申请日：2018-01-18

Applicant: ROHTO Pharmaceutical Co., Ltd.

Designer： Shigehiko Kokubo

公开(公告)号：US20180344775A1

公开(公告)日：2018-12-06

申请号：US15778362

申请日：2016-11-17

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Hayato Kurata ,  Hidenori Nonaka

IPC: A61K35/28 ,  A61P1/16 ,  C12N5/0775

CPC classification number: A61K35/28

Abstract: An object of the present invention is to provide a method for producing a therapeutic agent for liver diseases containing stromal cells derived from adipose tissue, which is excellent in convenience in preparation of a therapeutic agent while maintaining an excellent therapeutic effect on the stromal cells derived from adipose tissue against liver diseases, and a therapeutic agent for liver diseases obtained by such a producing method. The present invention is directed to a therapeutic agent for liver diseases containing stromal cells derived from adipose tissue which has been subjected to both cryopreservation and thawing at least twice.